Nirmatrelvir and ritonavir

Paxlovid is approved for mild-to-moderate COVID-19 in adults at high risk of progression to severe disease, including hospitalization or death. Start promptly after diagnosis and within 5 days of symptom onset. It is not approved as pre-exposure or post-exposure prophylaxis. Prior trial benefits are population-specific; no universal risk-reduction percentage is promised to every vaccinated or low-risk patient.

The current EUA covers high-risk patients age 12 and older weighing at least 40 kg with mild/moderate COVID-19. This is authorized use, not an established pediatric FDA-approved indication; under 12 or below 40 kg is not authorized. Assess severity, risk, organ function and feasibility of managing interactions. No regimen is supplied to initiate solely for established severe hospitalized disease; if hospitalization follows an already-started course, completion is at the treating clinician’s discretion.

Use the appropriate renal pack and prescribe the numeric amount of BOTH ingredients. The table gives the current U.S. PI regimens, also reflected in the current EUA for eligible patients; mild impairment eGFR 60 to < 90 needs no adjustment. Nirmatrelvir tablets are 150 mg each and ritonavir tablets 100 mg each. Do not reduce ritonavir by copying the nirmatrelvir reduction. On hemodialysis days, give the severe-renal dose after dialysis.

Start within 5 days of symptoms and complete the prescribed 5-day course. Take with or without food at approximately the same scheduled times; swallow whole without chewing, breaking or crushing. If a dose is missed within 8 hours of its usual time, take it and resume the schedule; if more than 8 hours late, skip and take the next scheduled dose. Never double. Dose-pack colors do not replace written renal instructions.

No adjustment is needed for Child-Pugh A or B hepatic impairment; severe Child-Pugh C is not recommended because PK/safety data are unavailable. Reassess renal function when unstable rather than assume an old result still selects the correct pack. No universal repeat, extended course, crushed-tablet, IV or under-authorized-age regimen is supplied.

Contraindicated with clinically significant nirmatrelvir/ritonavir/component hypersensitivity; with certain CYP3A-dependent drugs whose increased exposure is dangerous; and with strong CYP3A inducers that reduce antiviral exposure. Examples include amiodarone and specified antiarrhythmics, ranolazine, eplerenone/finerenone, oral midazolam/triazolam, lovastatin/simvastatin, voclosporin, suzetrigine and sildenafil for PAH. Colchicine is contraindicated with renal/hepatic impairment. Strong inducers include carbamazepine, phenytoin, phenobarbital/primidone, rifampin/rifapentine, apalutamide/enzalutamide, lumacaftor/ivacaftor and St. John’s wort. This is not an exhaustive interaction clearance list; consult the complete current table and companion labels.

The boxed warning concerns significant drug interactions from ritonavir’s strong CYP3A inhibition, potentially causing severe, life-threatening or fatal toxicity. Medication review, defined management steps and a benefit-risk assessment are required before treatment; five-day duration does not remove the warning.

Altered taste and diarrhea are the common trial reactions. Headache, abdominal pain, nausea/vomiting, hypertension and malaise have been reported during authorized use; serious allergy/skin reactions and drug-interaction toxicity need prompt assessment. Spontaneous reports cannot define precise event frequencies or establish causality for every report.

Review all §4 contraindicated drugs, including newer additions such as suzetrigine. Strong CYP3A induction persists after stopping an inducer, so Paxlovid cannot simply begin immediately after withholding carbamazepine, rifampin or another listed strong inducer. Do not tell patients to stop seizure, transplant or cardiac therapy independently to make treatment possible; an alternative antiviral or specialist plan may be needed.

For medically necessary Paxlovid, hold lovastatin/simvastatin at least 12 hours before starting, throughout the 5 days, and for 5 days after completion. Consider holding atorvastatin during the course; the label says it need not be withheld before or after treatment. Ethinyl estradiol exposure may fall: consider additional nonhormonal contraception during treatment and until one menstrual cycle after stopping. These are drug-specific instructions, not a universal statin restart rule.

Avoid rivaroxaban. Apixaban management depends on its prescribed dose; dabigatran depends on indication/renal function; follow the companion label. Monitor INR closely with warfarin. Tacrolimus/cyclosporine require expert dose management and close concentration monitoring during/after treatment; avoid co-use if such monitoring is infeasible. Avoid everolimus/sirolimus. Amlodipine and related calcium blockers may need reduction and BP/edema monitoring. Do not infer that all anticoagulants or transplant medicines share one hold schedule.

Fentanyl, hydrocodone, oxycodone and meperidine can cause enhanced, potentially fatal respiratory depression; consider prescribed reduction and close monitoring. Oral midazolam/triazolam are contraindicated; parenteral midazolam is a separately managed monitored-setting interaction. Avoid salmeterol. Sildenafil for PAH is contraindicated; tadalafil for PAH should be avoided, whereas ED PDE5 use needs the product-specific dose adjustment. Do not extrapolate PAH restrictions into a made-up universal ED dose.

Review additional label-table categories such as anticancer drugs, antiarrhythmics, anticonvulsants, psychotropics, migraine drugs, corticosteroids and antimicrobials; no short list establishes safety. Ritonavir/cobicistat-containing HIV therapy and ritonavir-containing HCV therapy generally continue as indicated with adverse-effect monitoring. Individual adjustment/restart decisions should be documented by the prescriber/pharmacist.

Current pediatric EUA requires BOTH age ≥ 12 and weight ≥ 40 kg; safety/effectiveness and optimal pediatric dosing are not established as an approved indication, and exposure support is extrapolated from adult data. Older adults need assessment of risk, kidney function and polypharmacy; the adult PI does not mandate an age-only reduction. The current EUA renal schedule is explicit rather than inferred from an older adult-only source.

Renal impairment increases nirmatrelvir exposure: use the current eGFR-specific dosing/frequency table, including the severe-renal/dialysis regimen. Give after dialysis on treatment dialysis days. Child-Pugh A/B require no adjustment;C is not recommended. Existing hepatitis or liver-enzyme abnormalities require caution despite the absence of a routine A/B reduction.

Nirmatrelvir pregnancy data remain insufficient to assess drug-associated fetal risk. Ritonavir observational data have not identified increased major-birth-defect risk, but do not establish absence of all pregnancy harms. Untreated maternal COVID-19 also carries maternal/fetal risk; individualize promptly with the clinical team rather than invent a pregnancy contraindication or guaranteed safety claim.

The current label reports low milk amounts of both ingredients, with estimated weight-adjusted infant doses about 1.8% for nirmatrelvir and 0.2% for ritonavir in a small study. Infant-outcome and milk-production data are unavailable; weigh maternal need and feeding benefits/risks. Combined hormonal contraception may be less effective; retain the additional nonhormonal precaution through one menstrual cycle after stopping.

Nirmatrelvir blocks SARS-CoV-2 main protease, preventing viral polyprotein processing needed for replication. Ritonavir is not active against that viral protease; it inhibits CYP3A metabolism and increases nirmatrelvir exposure. Giving nirmatrelvir alone can produce insufficient exposure. Protease target and boosting role differ from an HIV-treatment indication for this short-course co-pack.

In label healthy-subject studies, nirmatrelvir given with ritonavir peaks around 3 hours and ritonavir around 4 hours; mean half-lives are approximately 6 hours. Nirmatrelvir is about 69% protein-bound and predominantly renally eliminated when boosted; ritonavir is 98–99% bound and mainly hepatically metabolized. These study averages do not replace renal-dose or interaction assessment.

Renal dysfunction increases nirmatrelvir exposure; the current severe-renal regimen was evaluated in a small dedicated adult study. CYP3A substrates/transporters explain many interactions, while inducers reduce antiviral exposure. Current in-vitro variant activity and resistance data do not guarantee response to every future variant or justify unsupervised extra courses.

Establish diagnosis/symptom-onset timing, severe-disease risk, age/weight where applicable, current renal/hepatic information, allergy and full medication/herbal list. Define dose pack, interacting-drug holds/reductions, monitoring and restarts. Monitor clinical worsening, hydration and medication toxicity; use drug-specific levels/INR/BP/respiratory assessment when indicated. No universal new lab panel substitutes for an adequate organ/interaction assessment.

Under pediatric EUA, the prescriber/designee must report potentially related serious adverse events and medication errors to FDA within 7 calendar days of awareness, with a copy to Pfizer. Pharmacist prescribing requires sufficient organ-function and medication information; refer for clinician evaluation if medication modification or unavailable monitoring is needed.

Take all tablets for the prescribed dose together for 5 days; renal regimens differ. Swallow whole with or without food, follow the 8-hour missed-dose rule and do not double. Keep written instructions for paused medicines and do not restart them early without the defined plan. Report new medications during the course. Obtain urgent care for allergy, breathing difficulty, severe illness or suspected overdose.

Recurrent symptoms or a new positive test after improvement can occur with or without antivirals. Follow current isolation/transmission precautions and contact the clinical team if symptoms worsen or recur; do not self-prescribe a second course. Benefit in eligible high-risk patients is not negated solely by rebound. The CDC page’s older severe-kidney contraindication shorthand is superseded here by current PI/EUA renal dosing.

Nirmatrelvir 150 mg is a pink oval film-coated tablet marked PFE/3CL. One standard carton NDC 0069-5045-30 contains 30 tablets: 20 nirmatrelvir plus 10 ritonavir; that pack’s ritonavir is white/off-white capsule-shaped marked H/R9. Other current packs use white ovaloid ritonavir marked NK. Confirm the actual carton, tablets and renal directions rather than appearance alone.

Each nirmatrelvir tablet is 150 mg and each ritonavir tablet 100 mg. Standard five-day pack contains 30 total tablets; moderate-renal pack 20; severe-renal pack 11 (6 nirmatrelvir plus 5 ritonavir), with a larger Day 1 dose followed by smaller Days 2–5 doses. These are co-packaged tablets, not a single combined-strength tablet or a liquid/IV formulation.

Store 20–25°C with 15–30°C excursions. Keep tablets in their child-resistant blister until ready to take the dose, and keep away from children. Follow the correct pack’s daily instructions; do not casually transfer tablets into a generic twice-daily pill box that obscures severe-renal Day 1 versus Days 2–5 dosing.